Innovent Biologics' Humira Biosimilar Earns Chinese Approval

China’s National Medical Products Administration has approved Innovent Biologics’ Humira biosimilar Sulinno (adalimumab injection) for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis.

Sulinno’s clinical similarity to Humira was demonstrated in a phase 3 clinical trial that compared the two drugs for patients with ankylosing spondylitis. The results were published in the Lancet Rheumatology in 2019.

Humira is currently used around the world for 17 different indications, including ankylosing spondylitis, ulcerative colitis and Crohn’s disease.